Journal ArticleDOI
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Jon M. Hanifin,Thurston M,Thurston M,Omoto M,Omoto M,R. Cherill,R. Cherill,Susan J. Tofte,Graeber M,Graeber M +9 more
Reads0
Chats0
TLDR
In this paper, the reliability of the EASI scoring system was evaluated by assessing inter-and intra-observer consistency, and the results indicated that the evaluators assessed the patients consistently across both study days.Abstract:
:Objective– To test the reliability of the eczema area and severity index (EASI) scoring system by assessing inter- and intra-observer consistency. Design: Training of evaluators, application, and assessment over 2 consecutive days. Setting– An academic center. Patients– Twenty adults and children with atopic dermatitis (AD); cohort 1 (10 patients ≥8 years) and cohort 2 (10 patients <8 years). Interventions– None. Main outcome measure– The EASI was used by 15 dermatologist evaluators to assess atopic dermatitis in cohort 1 and cohort 2 on 2 consecutive days. Inter- and intraobserver reliability were analyzed. Results– Overall intra-evaluator reliability of the EASI was in the fair-to-good range. Inter-evaluator reliability analyses indicated that the evaluators assessed the patients consistently across both study days. Conclusions– This study demonstrated that the EASI can be learned quickly and utilized reliably in the assessment of severity and extent of AD. There was consistency among the evaluators between consecutive days of evaluation. These results support the use of the EASI in clinical trials of therapeutic agents for AD.read more
Citations
More filters
Journal ArticleDOI
Model-Based Meta-Analysis to Optimize Staphylococcus aureus‒Targeted Therapies for Atopic Dermatitis
TL;DR: In this paper , a model-based meta-analysis was performed to investigate the possible causes of these conflicting results and suggest how to improve the efficacies of S. aureus-targeted therapies.
Journal ArticleDOI
Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data.
Pavel Kovalenko,Mohamed A. Kamal,John D. Davis,Nidal Huniti,Christine Xu,Ashish Bansal,Brad Shumel,A. Thomas DiCioccio +7 more
TL;DR: In this article, a 2-compartment model with linear and Michaelis-Menten elimination and 3 transit compartments describing lag time in absorption was utilized to describe dupilumab pharmacokinetics in the pediatric populations.
Journal ArticleDOI
Emerging systemic therapies for atopic dermatitis: oral small molecules and targeted topical agents.
TL;DR: Targeted therapeutics including oral small molecules and topical agents show promise for the treatment of atopic dermatitis and the use of validated core measures is necessary for future trials to adequately compare agents and progress evidence-based medicine.
Journal ArticleDOI
DESCRIBE-AD: A novel classification framework for atopic dermatitis
TL;DR: In this article , the authors proposed a framework to assess atopic dermatitis based on a literature review and clinical experience, which can effectively capture the clinical domains contributing to AD heterogeneity and includes both patient and clinician-reported perspectives.
Journal ArticleDOI
Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older.
Eric L. Simpson,Amy S. Paller,Amy S. Paller,Elaine C. Siegfried,Elaine C. Siegfried,Diamant Thaçi,Andreas Wollenberg,Michael J. Cork,Michael J. Cork,Danielle Marcoux,Danielle Marcoux,Rui Huang,Zhen Chen,Ana B. Rossi,Brad Shumel,Debra Sierka,Ashish Bansal +16 more
TL;DR: In phase-III trials in adolescents and children with atopic dermatitis (AD), dupilumab significantly decreased global disease severity and extent of AD across different anatomical regions as mentioned in this paper.
References
More filters
Book
The design and analysis of clinical experiments
TL;DR: The Parallel Groups Design as mentioned in this paper is a special case of the Parallel Groups Study, and it is used to control for prognostic variables in linear regression analysis of linear regressions of linear models.
Journal ArticleDOI
Severe psoriasis--oral therapy with a new retinoid.
T. Fredriksson,Ulf Pettersson +1 more
TL;DR: Ro 10--9359 proved to be an extremely potent antipsoriatic drug and a more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment.
Journal ArticleDOI
Severity Scoring of Atopic Dermatitis: The SCORAD Index
K.U. Schallreuter,Ch. Levenig,J. Berger,J. Umbert,R.K. Winkelmann,L. Wegener,O. Correia,Olivier Chosidow,P. Saiag,S. Bastuji-Garin,J. Revuz,Jean-Claude Roujeau,R. Situ,D.R. Inman,S.E.G. Fligiel,J. Varani,R.E. Schopf,J. Dobmeyer,T. Dobmeyer,B. Morsches,K. Holubar,G.E. Piérard,O. Bongard,H. Bounameaux,P. Corcuff,J.-L. Lévêque,J. Brasch,E. Christophers,G.T. Nahass,M. Sisto,S.A. Wagner,R.U. Peter,O. Adam,T. Ruzicka,J. McGrath,N.P. Burrows,R. Russell Jones,R.A.J. Eady,S. Veraldi,G. Rizzitelli,G. Lunghi,R. Cardone,R.M. Trüeb,G. Burg,F. Wantke,G. Fleischl,M. Götz,R. Jarisch,G. Tadini,E. Ermacora,S. Cambiaghi,A. Brusasco,R. Cavalli +52 more
TL;DR: Assessment methods for atopic dermatitis are not standardized, and therapeutic studies are difficult to interpret, so consensus on these methods is needed to obtain a consensus on them.
Journal ArticleDOI
Large sample standard errors of kappa and weighted kappa.
TL;DR: The statistics kappa and weighted kappa (Cohen, 1960) were introduced to provide coefficients of agreement between two raters for nominal scales as discussed by the authors, and they were used to provide a measure of the relative seriousness of the different possible disagreements.
Related Papers (5)
Severity Scoring of Atopic Dermatitis: The SCORAD Index
K.U. Schallreuter,Ch. Levenig,J. Berger,J. Umbert,R.K. Winkelmann,L. Wegener,O. Correia,Olivier Chosidow,P. Saiag,S. Bastuji-Garin,J. Revuz,Jean-Claude Roujeau,R. Situ,D.R. Inman,S.E.G. Fligiel,J. Varani,R.E. Schopf,J. Dobmeyer,T. Dobmeyer,B. Morsches,K. Holubar,G.E. Piérard,O. Bongard,H. Bounameaux,P. Corcuff,J.-L. Lévêque,J. Brasch,E. Christophers,G.T. Nahass,M. Sisto,S.A. Wagner,R.U. Peter,O. Adam,T. Ruzicka,J. McGrath,N.P. Burrows,R. Russell Jones,R.A.J. Eady,S. Veraldi,G. Rizzitelli,G. Lunghi,R. Cardone,R.M. Trüeb,G. Burg,F. Wantke,G. Fleischl,M. Götz,R. Jarisch,G. Tadini,E. Ermacora,S. Cambiaghi,A. Brusasco,R. Cavalli +52 more